Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)
The Institute for Genomic Research (TIGR) (now The J. Craig Venter Institute)
Jim is a co-founder of Faber and successfully handles a wide range of agreements for pre-clinical research and related activities at companies and non-profit organizations in the life sciences. He focuses on transactions that advance early stage research and development of novel therapeutic assets and applications for unique technologies. These agreements cover the spectrum from discovery to development and commercialization - evaluations, sponsored research, option rights and exclusive development and commercialization licenses. His work in recent years includes helping commercial clients access scientific expertise at prominent academic or non-profit entities as part of a strategy to investigate or validate technologies.
Jim drafted several agreements covering multi-party consortia among industry and non-profit entities, sorting the respective interests and goals for the contributions of each party and providing advice on how to manage the results of joint work. He advises venture-backed companies about and assists in their negotiations with universities and non-profit research institutions for research programs, licenses and options, helping to align respective interests for the transfer of intellectual property from academia to industry.
Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)
Counsel
The Institute for Genomic Research (TIGR) (now The J. Craig Venter Institute), one of the first non-profit research centers to incorporate novel technologies in large-scale gene discovery research.
Counsel